Royalty Report: Drugs, Drug Discovery, Cancer – Collection: 263910

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Drug Discovery
  • Cancer
  • ribonucleic acid
  • Diagnostic
  • Medical
  • Vaccine
  • HIV / AIDs
  • Proteins
  • Molecular
  • Research
  • cardiac
  • Diabetes Treatment
  • Fibrosis
  • Respiratory
  • Therapeutic
  • Biotechnology
  • Genome

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 263910

License Grant
The University grants the Israeli Licensor a co-exclusive, world-wide license to make, have made, use, have used, import, sell, have sold, and offer for sale Licensed Products in the Field of Use during the Term.
License Property
The technology relates to microRNA sequences.  The patents are for Anti Micro-RNA Oligonucleotide Molecules;  Pancreatic Islet MicroRNAs and Methods for Inhibiting Same;   DNA Virus MicroRNAs and Methods for Inhibiting Same; and,  Human MicroRNAs and Methods for Inhibiting Same.
Field of Use
The term Field of Use means human and animal therapeutics.

MicroRNAs have been shown to hold tremendous potential as a new class of prospective drug targets with significant therapeutic opportunity.

MicroRNAs (miRNAs) are a recently discovered, naturally occurring form of RNAi. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNA expression levels have been shown to be correlated with various disease states and to hold great potential as diagnostics and prognostic markers

Licensee's lead therapeutic development program for liver cancer (hepatocellular carcinoma or HCC) has so far identified four microRNAs that when inhibited in vitro lead to a decrease in liver cancer cell proliferation.

IPSCIO Record ID: 203324

License Grant
The German Licensor grants the Israeli Licensee a worldwide non-exclusive license under the Patent Rights of a German non-profit research organization who has authorized the Licensor as its technology transfer agent, to make, have made, use, import, sell, have sold and offer for sale Licensed Products and Licensed Services.
License Property
The patents and licensed products are relating to microRNA sequences and Small expressed RNA molecules.

MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. As a result, these differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body.

Field of Use
The term Field Of Use means the sale and use of Licensed Products as research products for research purposes, including use of such products in the provision of research services to third parties. Specifically excluded from the Field of Use is any use for diagnostic or therapeutic purposes, whether said use is in vivo or in vitro, and any use in humans, for whatever purpose.

IPSCIO Record ID: 362503

License Grant
University grants to Israeli Licensee and its Affiliates a nonexclusive, world-wide license to make, have made, use, import, sell, have sold and offer for sale Licensed Products in the Field of Use during the Term. Licensee has no right to sublicense except as set forth. University grants no other rights or licenses.
License Property
Intellectual property owned by the University relates to microRNA sequences.

University Patent Rights means all patent rights represented by or issuing from (a) the United States patent applications; (b) any continuation, divisional and re-issue applications of (a); and (c) any foreign counterparts and extensions of (a) or (b).

microRNAs have the potential to form the basis of a novel class of diagnostic tests and therapies for many serious illnesses, including cancer and infectious diseases.

Field of Use
Field Of Use means the sale and use of research products including use of such products in the provision of services to third parties. Specifically excluded from the Field of Use is any use for diagnostic or therapeutic purposes, whether said use is in vivo or in vitro.

Field of use relates to microRNA. MicroRNAs are known as genes and naturally expressed, or produced, using instructions encoded in DNA and are believed to play an important role in regulating protein production. Proteins control most biological processes and thus we believe that microRNAs as their regulators have the potential to form the basis of a novel class of diagnostic tests and therapies for many serious illnesses. We have a four-part business model (each of which is referred to herein as a “Line of Business”) designed to capitalize on a number of different approaches to the development and commercialization of microRNA-based therapies and diagnostics.

IPSCIO Record ID: 362456

License Grant
University hereby grants to Israeli Licensee an exclusive license to make, have made, manufacture, provide, use, import, commercialize, distribute, offer for sale and sell the licensed product(s) in the United States and worldwide under the patent rights. This Grant shall apply to the Licensee and any affiliated company, except that any affiliated company shall not have the right to grant a sublicense to others as set forth. If any affiliated company exercises rights under this Agreement, such affiliated company shall be bound by all terms and conditions of this Agreement, including but not limited to indemnity and insurance provisions and royalty payments, which shall apply to the exercise of the rights, to the same extent as would apply had this Agreement been directly between University and the affiliated company. In addition, Licensee shall remain fully liable to University for all acts and obligations of affiliated company such that acts of the affiliated company shall be considered acts of the Licensee.
License Property
Patent Rights shall mean the (i) U.S. patent application, assigned to University entitled
“Discovery of Human miRNAs and Their Evaluation with a Dicer KO” and the invention disclosed and claimed therein, (ii) all continuations, divisions, and reissues based thereon, (iii) claims of continuation-in-part applications directed to subject matter specifically described in (i), (iv) any corresponding foreign patent applications, and (v) any U.S. patents, or foreign patents issuing, granted or registered on any of (i) through (iv).

Licensed Product)s) as used herein in either singular or plural shall mean any process or method, material, compositions, drug, or other product or service, the manufacture, use, provision or sale of which would constitute, but for the license granted to Licensee pursuant to this Agreement, an infringement of a valid claim of patent rights relating to a nucleic acid sequence (infringement shall include, but is not limited to, direct, contributory, or inducement to infringe).

Field of Use
Field of use is for diagnostic tests and therapies for many serious illnesses, including cancer and infectious diseases.

These diagnostic and therapeutic products relates to a discovered group of genes known as microRNAs. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are believed to play an important role in regulating protein production.

microRNAs have the potential to form the basis of a novel class of diagnostic tests and therapies for many serious illnesses, including cancer and infectious diseases.

IPSCIO Record ID: 362450

License Grant
Licensor hereby grants to French Licensee a worldwide, royalty-bearing, exclusive license, with the right to grant sublicenses as set forth, under the Licensor Know-How and Licensor Patents to Research, Develop, make, have made, use, gain Approval, Commercialize, sell, offer for sale, have sold, export and import Licensed Compounds and Products and Companion Diagnostics in the Product Field. The licenses granted to Licensee are sublicensable only in connection with a sublicense of a Licensed Compound or Product to any Affiliate of Licensee or to any Third Party, in each case to Research Develop, make, have made, use, gain Approval, Commercialize, sell, offer for sale, have sold, export and import Licensed Compound or Product in the Product Field in accordance with the terms of this Agreement.
License Property
Licensed Compound means either (i) with respect to any Collaboration Target identified in this Agreement as approached via a microRNA Antagonist, any microRNA Antagonist that modulates the expression of such Collaboration Target where its primary mechanism of action is through its hybridization to such Collaboration Target, or (ii) with respect to any Collaboration Target identified in Agreement as approached via a microRNA Mimic, a microRNA Mimic with a substantially similar base composition as such Collaboration Target and which is designed to mimic the activity of such Collaboration Target. For purposes of clarity, so long as Mir-21 remains a Collaboration Target, a Mir-21 Compound will be a Licensed Compound under this Agreement.
Collaboration Targets Mir-21 MIMAT0000076 microRNA Antagonist

Product means any pharmaceutical product containing a Licensed Compound (alone or with other active ingredients), in all forms, presentations, formulations and dosage forms.

microRNA means a structurally defined functional RNA molecule usually between 21 and 25 nucleotides in length, which is derived from genetically-encoded non-coding RNA which is predicted to be processed into a hairpin RNA structure that is a substrate for the double-stranded RNA-specific ribonuclease Drosha and subsequently is predicted to serve as a substrate for the enzyme Dicer, a member of the RNase III enzyme family; including, without limitation, those microRNAs exemplified in miRBase (http//microrna.sanger.ac.uk/). To the extent that scientific developments after the Effective Date would lead experts in the field of micro RNA to
expand this definition of microRKA, the Parties agree to discuss redefining microRNA for purposes of this Agreement; provided, however, that nothing contained herein will require any Party hereto to expand this definition.

microRNA Compound means a compound consisting of (a) a microRNA Antagonist, or (b) a microRNA Mimic.

microRNA Antagonist means a single-stranded oligonucleotide (or a single stranded analog thereof) that is designed to interfere with or inhibit a particular microRNA. For purposes of clarity, the definition of “microRNA Antagonist” excludes oligonucleotides that function predominantly through the RNAi mechanism of action or the RNase H mechanism of action.

microRNA Mimic means a double-stranded or single-stranded oligonucleotide or analog thereof with a substantially similar base composition as a particular microRNA and which is designed to mimic the activity of such microRNA.

Mir-21 means the microRNA having (i) miRBase ID hsa-miR-21; (ii) the miRBase Accession Number MIMAT0000076, and (iii) the sequence UAGCUUAUCAGACUGAUGUUGA.

Mir-21 Compound means any microRNA Antagonist that modulates the expression of Mir-21 whose primary mechanism of action is through its hybridization to Mir-21.

Mir-21 Product means any pharmaceutical product containing a Mir-21 Compound (alone or with other active ingredients), in all forms, presentations, formulations and dosage forms.

Licensor Core Technology Patents means, Patents Controlled by Licensor or its Affiliates on the Effective Date and/or at any time thereafter, in each case that are useful or necessary for the Development and Commercialization of Licensed Compound and Products. Licensor Core Technology Patents will exclude the Product Specific Patents. A representative list of the Licensor Core Technology Patents as of the Effective Date is listed hereto. For clarification, any Licensor Program Patent or any Joint Patent satisfying the definition above will be considered a Licensor Core Technology Patent.
7,838,660 – MicroRNA molecules
7,838,662 – Microrna molecules

Product Specific Patents means all Patents (including all claims and the entire scope of claims therein) Controlled by Licensor or its Affiliates on the Effective Date and/or at any time thereafter, in each case claiming (a) a Collaboration Target gene sequence or a portion thereof, (b) the specific compositions of matter of Licensed Compounds or Products, or (c) methods of using Licensed Compounds or Products as therapeutics; provided however, that
(1) unless the Parties otherwise agree in writing, Patents that include claims that are directed to subject matter and have a scope that is applicable to microRNA Compounds in general, and not directed solely to Licensed Compounds or Products or to the Collaboration Taget gene sequence or a portion thereof, will be considered to be Licensor Core Technology Patents; and
(2) unless the Parties otherwise agree in writing, Patents that include claims that are directed to the identification or isolation of microRNAs that are not Collaboration Targets, or to the production, composition, or use of microRNA Compounds that are not Licensed Compounds or Products, will be considered to be Licensor Core Technology Patents.
For clarification, any Licensor Program Patent or any Joint Patent satisfying the definition above, will be considered a Product Specific Patent. The Product Specific Patents as of the Effective Date are listed hereto.
7,723,510 – MicroRNA molecules

Product Field means (a) with respect to Licensed Compounds and Products, the treatment and/or prophylaxis of any Indication and (b) with respect to Companion Diagnostics, to the extent that Licensor Controls diagnostic rights, detecting the applicable Collaboration Target as a biomarker for identifying patient populations that are better suited to respond to the corresponding Product in the treatment and/or prophylaxis of an approved Indication for the Product.

Field of Use
'Therapeutic Field' means any field concerning the remediation of a health problem, including Fibrosis, [Immunology], oncology, diabetes, cardiovascular, ophthalmology, central nervous system, internal medicine, thrombosis, and vaccines.

IPSCIO Record ID: 362448

License Grant
German Licensor grants to Licensee during the Term a co-exclusive, worldwide, royalty-bearing license under the Licensors Institute Patent Rights to develop, have developed, make, have made, use, have used, import, have imported, offer for sale, sell and have sold Licensed Products, and to develop, perform, have performed, offer for sale, sell and have sold Licensed Services, each in the Field. Licensee shall have the right to grant sublicenses to the rights granted to it under this Agreement to Third Parties, without seeking consent from Licensor as long as they comply with the terms in the Agreement.
License Property
MPG Patent Rights relate to certain microRNA (Small expressed RNA molecules) sequences discovered by scientists of Licensor.

microRNAs are naturally occurring ribonucleic acid ('RNA') molecules that play a critical role in regulating key biological pathways. Scientific research has shown that an imbalance, or dysregulation, of microRNAs is directly linked to many diseases. Furthermore, many different infectious pathogens interact and bind to host microRNA to survive. To date, over 500 microRNAs have been identified in humans, each of which can bind to multiple messenger RNAs that control key aspects of cell biology. Since many diseases are multi-factorial, involving multiple targets and pathways, the ability to modulate multiple pathways by targeting a single microRNA provides a new therapeutic approach for treating complex diseases.

Licensors Institute Patent Rights shall mean
US Patent Application No. [10/490,955] filed [15-09-2004] (resulting from the PCT appl.)

Licensed Products shall mean any product (i) that, or the development, manufacture, use or sale of which, absent the license granted hereunder, would infringe one or more Pending Claims or Valid Claims of the Licensors Institute Patent Rights, or (ii) which is developed or manufactured by using a Licensed Process or that, when used, practices a Licensed Process. For the purpose of this Agreement, diagnostic kits shall be considered as Licensed Products, and Net Sales of diagnostic kits shall be considered as Net Sales of Licensed Products, if and to the extent such diagnostic kits contain Licensed Products as a diagnostically active product component, together with other diagnostically non-active product components (including without limitation buffers, purification components, or hardware such as tubes, plates, glassware).

Field of Use
microRNAs are recently discovered, naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown the improper balance, or dysregulation, of microRNAs is directly linked to many diseases. We believe we have assembled the leading position in the microRNA field, including expertise in microRNA biology and oligonucleotide chemistry, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development processes.

Field shall mean sale and use of Licensed Products, or performance and sale of Licensed Services, for
(a) Licensee’s internal and collaborative research and development purposes, and
(b) Diagnostic Purposes, specifically excluding any sale and use of Licensed Products, or performance and sale of Licensed Services, for Research Purposes or for Therapeutic Purposes.

IPSCIO Record ID: 362451

License Grant
Licensor hereby grants French Licensee the nonexclusive, nontransferable right, exercisable in accordance with this Agreement to obtain the nonexclusive license set forth under the terms and conditions set forth in this Agreement to conduct Research on microRNA Compounds, including a technology sharing from Licensor; and (ii) an exclusive license to Develop and Commercialize a limited number of microRNA Compounds as Option Products.

Commercial License Licensor will grant to Licensee a worldwide, royalty-bearing, exclusive license, with the right to grant sublicenses as set forth, under the Licensor Platform Technology to Research, Develop, make, have made, use, gain Approval, Commercialize, sell, offer for sale, have sold, export and import Option Compounds and Option Products. The licenses granted to Licensee are fully sublicensable to any Affiliate of Licensee, and only sublicensable to a Third Party in connection with a sublicense of an Option Compound or Option Product for the continued Research, Development and Commercialization of such Option Compound or Option Product in accordance with the terms of this Agreement.

License Property
microRNA Compound means a compound consisting of (a) a microRNA Antagonist, or (b) a microRNA Mimic.

microRNA Antagonist means a single-stranded oligonucleotide (or a single stranded analog thereof) that is designed to interfere with or inhibit a particular microRNA.

microRNA Mimic means a double-stranded or single-stranded oligonucleotide or analog thereof with a substantially similar base composition as a particular microRNA and which is designed to mimic the activity of such microRNA.

Option Compound means either (i) with respect to Option Targets for which Licensee has selected a microRNA Antagonist under Section 3.1 above, any microRNA Antagonist discovered by Licensee or its Affiliates that modulates the expression of such Option Target where its primary mechanism of action is through its hybridization to such Option Target, or (ii) with respect to Option Targets for which Licensee has selected a microRNA Mimic under Section 3.1 above, a microRNA Mimic discovered by Licensee or its Affiliates with a substantially similar base composition as the applicable Option Target and which is designed to mimic the activity of such Option Target.

Licensor Platform Technology Patents means, (A) all Patents Controlled by Licensor on the Effective Date and listed in Agreement and (B) all Patents Controlled by Licensor during the IP Period that claim (a) microRNA Compounds in general, (b) chemistry or delivery technology useful technology useful in connection with microRNA Compounds, (c) general mechanisms of action by which a microRNA Compound modulates microRNAs, or (d) general methods of treating or preventing an Indication by modulating one or more microRNAs; provided, however, that in each case, Licensor Platform Technology Patents do not include (1) any Patents Controlled by Licensor or its Affiliates to the extent that such Patents claim (a) the sequence or a portion thereof corresponding to a specific microRNA sequence or a portion thereof, (b) the specific composition of matter of any microRNA Compound, (c) methods of using as a therapeutic any microRNA Compound; (2) the Tuschl 3 Patents; and (3) the Rockefeller Patents.

Field of Use
The collaboration and license agreement which we subsequently amended, restated and superseded in July 2012 is to develop and commercialize licensed compounds targeting four microRNA alliance targets initially focused in the field of fibrosis.  The July 2012 amended and restated agreement expanded the alliance to include potential microRNA therapeutics in oncology.
Field of use is for therapeutic applications relating to orphan diseases and oncology targets.

IPSCIO Record ID: 344587

License Grant
Licensor grants to the Canadian Licensee an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and under the Licensor Core Technology Patents, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import Products.
License Property
Licensor is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to identify and commercialize novel drugs.

Antisense Compound means an oligomeric compound or analog, mimic or mimetic thereof having a sequence that is partially or wholly complementary to the sequence of a messenger RNA (pre-mRNA or mRNA), viral RNA, or noncoding RNA that directly modulates RNA expression.

Product means a pharmaceutical preparation comprising any single TS ASO or Tandem selected by Licensee. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each TS ASO which constitutes the active pharmaceutical ingredient in each Product.

TS ASO means a single-stranded oligonucleotide or an analog thereof that hybridizes to TS mRNA using Watson-Crick base pairing and inhibits production of TS via an RNase-H mechanism.

1. U.S. Patent No. 6,001,1653
2. PCT Publication No. WO 93/13121
3. U.S. Patent. 5,914,396
4. U.S. Patent 61451,991
5. U.S. Patent No. 6,166,197
6. U.S. Patent No. 51919,619
7. U.S. Patent No. 5,962,425
8. U.S. Patent No. 6,143,881
9. U.S. Patent No. 5,969,116
10. U.S. Patent No. 6,346,614
11. U.S. Patent No. 6,399,754
12. U.S. Patent No. 6,326,199

Field of Use
The field of use is the identification of a lead TS ASO targeted to inhibit Thymidylate Synthase.

The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies, antisense inhibition of TS suppressed human tumor cell growth and overcame tumor cell resistance to marketed TS-targeted drugs.

TS is an important target in a wide variety of cancers including, colorectal, breast, stomach, esophageal, head and neck cancers, and mesothelioma; it is of increasing importance in non-small cell lung cancer. In addition to interfering with the effectiveness of chemotherapy, the TS gene may also participate in causing cancer. TS is a target for several chemotherapy agents, including 5-fluorouracil (5-FU), pemetrexed (Alimta®), and raltitrexed (Tomudex®).

IPSCIO Record ID: 362516

License Grant
The University grants to an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale University Licensed Products.

This license grant is exclusive with respect to Universitys rights, except that University may use and permit other nonprofit organizations to use the University Patent Rights for educational and research purposes and not for sale or offer of sale.

License Property
The University controls certain intellectual property developed related to pathogenic viral proteins which control host cell functions.
Field of Use
Licensee is a biopharmaceutical company engaged in the discovery and development of drugs and DNA vaccines for the treatment of infectious diseases, including the HIV and hepatitis C viruses, as well as cancer and inflammatory diseases.

IPSCIO Record ID: 344567

License Grant
Licensor grants
For the Development License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Profit-Share Territory, and an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Royalty Territory.

For the Commercialization License, an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology to Commercialize Licensed Products in the Field in the Territory.

For the Manufacturing License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Manufacture or have Manufactured Licensed Products for Development and Commercialization in the Field for the Territory.

License Property
Patents includes, among other
RNAI Modulation of RSV and Therapeutic Uses Thereof,
Inhaled Treatment for RSV,
Methods and Compositions for Prevention or Treatment of RSV Infection,
Model for RSV Infection,
Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences,
Use of Double Stranded RNA For Identifying Nucleic Acid Sequences That Modulate the Function of a Cell, and, Influenza siRNA Molecules, Expression Constructs. Compositions. and Methods of Use.

Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

ALN-RSV01 is a synthetic double-stranded RNA (dsRNA) oligonucleotide formed by the hybridization of two partially complementary single-strand RN As in which the 3 ends of each strand are capped with two thymidine units (dT).

ALN-RSVO1 drug product is formulated as a sterile phosphate-buffered solution for dilution with normal saline prior to administration.

Licensed Products means any RNAi Product directed to RSV.

RSV means all strains of the respiratory syncytial virus.

RSVOl Product means any product containing Licensors proprietary composition known as ALN-RSVO1.

RSV02 Product means any product containing Licensors proprietary composition designated by the JSC as ALN-RSV02.

Field of Use
ALN-RSV01 is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients, as well as several other potent and specific second-generation RNAi-based RSV inhibitors in pre-clinical studies.

Directly Competitive Product means any therapeutic or prophylactic product that specifically targets RSV. For avoidance of doubt, Directly Competitive Product as to a Party shall not include a product with broad antiviral activity that may also target RSV as long as any Development of such product as a treatment or
prophylaxis of RSV in humans has been limited to discovery, research and preclinical Development work up to, but not including, IND-enabling studies.

Licensee will develop and commercialize such therapeutic RNA interference products for the treatment of respiratory infections in humans caused by RSV, throughout the world, excluding Japan and certain other countries in Asia.

IPSCIO Record ID: 365329

License Grant
This amendment, included with this agreement, updates the financial terms, including the royalty rates.

By the original agreement, University grants to an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale University Licensed Products.

This license grant is exclusive with respect to Universitys rights, except that University may use and permit other nonprofit organizations to use the University Patent Rights for educational and research purposes and not for sale or offer of sale.

License Property
The University controls certain intellectual property developed related to pathogenic viral proteins which control host cell functions.
Field of Use
Licensee is a biopharmaceutical company engaged in the discovery and development of drugs and DNA vaccines for the treatment of infectious diseases, including the HIV and hepatitis C viruses, as well as cancer and inflammatory diseases.

IPSCIO Record ID: 306496

License Grant
The Licensee was granted an exclusive license to certain Intellectual Property.
License Property
Licensor is the exclusive licensing agent for a University and representing Mayo Clinic’s interests in certain patents and intellectual property rights.  The Intellectual Property encompasses the inhibition of tumor growth using compounds that inhibit QSOX1 enzymatic activity and, specifically, to anti-neoplastic compounds targeting QSOX1 (the parent molecule referred to as SBI-183).

The enzyme Quiescin Sulfhydryl Oxidase 1 (QSOX1) is a master regulator of extracellular matrix remodeling, and its overexpression by tumor cells.  Overexpression of QSOX1 has been unambiguously linked to promoting tumor invasion and metastasis.  It has been discovered that a small molecule SBI-183 inhibited the enzymatic activity of QSOX1 and as a result suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo.

This license is to technology relating to SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis.  Small molecule SBI-183 inhibited the enzymatic activity of QSOX1 and as a result suppressed tumor cell invasion in vitro and metastasis of breast tumor cells in vivo. Through its medicinal chemistry efforts the Licensee synthesized multiple structural analogs of SBI-183 and unveiled SPX-1009 lead compound that demonstrated ten-fold improvement in suppressing invasion and metastasis in several cancer models.

SBI-183 enhances the activity of cytotoxic drugs in vitro.

Field of Use
Licensee was formed to develop a unique biomarker for cancer (QSOX1) as well as cancer diagnostic and therapeutic products based on QSOX1.  Licensee is a research and development company that aims to improve global cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis.

IPSCIO Record ID: 211894

License Grant
The German Licensor grants the Israeli Licensee a co-exclusive, worldwide, royalty-bearing license under the Licensed Patent Rights to develop, have developed, make, have made, use, have used, import, have imported, sell and have sold Licensed Products, and to perform, have performed, sell and have sold Licensed Services, each in the Field.

In order to establish co-exclusivity, Licensor shall not grant, during the Term, more than three other co-exclusive licenses to the Licensed Patent Rights in the Field with the scope of Other Diagnostic Licenses, or the Other Diagnostic Licensees.

Licensee shall have the right to grant sublicenses.

License Property
Diagnostic kits shall be considered as Licensed Products.

The Platform Technologies shall mean any technology for qualitative and/or quantitative detection or quantification of nucleic acids and genotyping used in the performance of a Licensed Service or offered as part of a Licensed Product, including, without limitation, RNA extraction and/or PCR technologies, including, without limitation, realtime based, microarray technologies, or any current or future technology providing substantially similar results.by any means.

Patents filed are for Small expressed RNA molecules (MicroRNA molecules).

Analyte Specific Reagents or ASRs shall mean antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents which, through specific binding or chemical reaction with substances in a specimen, are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens. ASRs that otherwise fall within this definition shall not fall within this definition when they are sold to in vitro diagnostic manufacturers for the purpose of manufacturing in vitro diagnostic products, or organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners, e.g., forensic, academic, research, and other non-clinical laboratories.

Field of Use
The Field shall mean sale and use of Licensed Products, or performance and sale of Licensed Services, for Licensees internal and collaborative research and development purposes, and Diagnostic Purposes, specifically excluding any sale and use of Licensed Products, or performance and sale of Licensed Services, for Research Purposes or for Therapeutic Purposes.  This agreement is to develop and commercialize products and services for Diagnostic Purposes.

The licensed microRNAs sequences will be added to Licensee microRNA database, providing the company with additional biomarker candidates for its diagnostic development programs.  Under the terms of the agreement, Licensee will be able to use these microRNAs to advance multiple research and development programs targeting new microRNA-based diagnostic tools for a variety of diseases.

IPSCIO Record ID: 362447

License Grant
Licensor hereby grants to English Licensee a worldwide, exclusive, royalty-bearing, sublicenseable license, under the Licensor Patents solely to Develop, Manufacture and Commercialize SPC-3649 in the Field.

Licensor possesses proprietary technology and know-how related to the research, discovery, identification, synthesis and development of single-stranded oligonucleotide miRNA Antagonists in the Field.

Licensee shall have the right to grant to its Affiliates and/or Third Parties sublicenses under the license granted solely to continue the Development, Manufacture or Commercialization of SPC-3649.

Licensor provides Licensee an option to a nonexclusive License to the Tuschl 3 Patents upon written notice, then grant by Licensor to Licensee a worldwide, nonexclusive, royalty-bearing, sublicenseable license, under the Tuschl 3 Patents solely to Develop, Manufacture and Commercialize SPC-3649 in the Field.

License Property
SPC-3649 shall mean (a) the proprietary Santaris compound known on the Effective Date as SPC-3649, and (b) any and all salts, crystalline and amorphous forms, and solvates (including hydrates) thereof. The sequence and chemistry of SPC-3649 is described in PCT Publication WO 2007/112754, published October 11, 2007.

SPC-3649 Product means any product that includes SPC-3649 as an active ingredient, or includes SPC-3649 in any base form, salt form, prodrug, ester, crystalline polymorph, hydrate or solvate thereof, whether or not as the sole active ingredient and in any dosage, form or formulation, sold by Licensee, its Affiliates or Sublicensees, in finished product form, packaged and labeled for sale. Unless otherwise indicated by context, Product or SPC-3649 Product includes Combination Products.

miRNA shall mean a structurally defined functional RNA molecule usually between 21 and 25 nucleotides in length, which is derived from genetically-encoded non-coding RNA which is predicted to be processed into a hairpin RNA structure that is a substrate for the double-stranded RNA-specific ribonuclease Drosha and subsequently is predicted to serve as a substrate for the enzyme Dicer, a member of the RNase III enzyme family; including, without limitation, those miRNAs exemplified in miRBase. To the extent that scientific developments after the Effective Date would lead experts in the field of miRNA to expand this definition of miRNA, the Parties agree to discuss redefining miRNA for purposes of this Agreement; provided, however, that nothing contained herein shall require any Party hereto to expand this definition.

miRNA Antagonist shall mean a single-stranded oligonucleotide (or a single stranded analog thereof) that is designed to interfere with or inhibit a particular miRNA. For purposes of clarity, the definition of “miRNA Antagonist” is not intended to include oligonucleotides that function predominantly through the RNAi mechanism of action or the RNase H mechanism of action.

miRNA Compound shall mean a compound consisting of a miRNA Antagonist. For purposes of clarity, miRNA Compound excludes (a) rniRNA Precursor Antagonists and (b) rniRNA Mimic.

Licensor Patents shall mean
(a) all Founding Company Patents Controlled by Licensor or any of its Affiliates as of the Effective Date and/or after the Effective Date and having an earliest priority date of no later than the Effective Date, including without limitation those listed
7,307,067 – Methods and compositions for reducing viral genome amounts in a target cell

(b) all Patent Rights, other than Founding Company Patents, Controlled by Licensor or any of its Affiliates as of the Effective Date and/or after the Effective Date and having an earliest priority date of no later than the Effective Date, including without limitation the Patent Rights listed
7,307,067 – Methods and compositions for reducing viral genome amounts in a target cell

in each case, that are necessary to Development, Manufacture or Commercialize SPC-3649 in the Field provided, however, that in each case of (a) through (b), (y) for any Patent Right that is the subject of an Additional Third Party Agreement, the provisions of the agreement will govern whether such Patent Right will be included as a Licensor Patent hereunder, and (z) unless the Parties enter into a Tuschl 3 Sublicense under this Agreement , Licensor Patents will exclude the Tuschl 3 Patents.

Tuschl 3 Patents means all Patent Rights licensed by Isis and/or Alnylam under the License Agreement among Max Plank Innovation GmbH (formerly Garching Innovation GmbH), Isis and Alnylam dated October 18, 2004, as amended. A representative list of the Tuschl 3 Patents as of the Effective Date is attached hereto
7,232,806 – MicroRNA molecules

miR-122 is a liver-expressed microRNA that has been shown to be a critical endogenous “host factor” for the replication of HCV, and anti-miRs targeting miR-122 have been shown to block HCV infection (Jopling et al. (2005) Science 309, 1577-81).

Field of Use
Field shall mean the treatment and/or prophylaxis of hepatitis C virus.

The collaboration is to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication.

IPSCIO Record ID: 274931

License Grant
The Israeli Licensor hereby grants to the Israeli Licensee the sole and exclusive worldwide license, even as to Licensor, under its part in the Research Results and the and Patent Rights, including the right to grant sublicenses on the terms set forth herein, to research, develop, use, import, offer for sale, market, commercialize, manufacture, distribute and sell the Products in the Territory.
License Property
Patent Rights shall mean United States and foreign patents and patent applications (which shall be deemed to include certificates of invention and applications for certificates of invention) which as of the Effective Date or at any time during the term of this Agreement relate in any way to Research ResultsResearch Results shall mean any and all microRNAs expression profiling data measured on the Materials, and its analysis pertaining to potential diagnostic application, as determined in the course of the performance of the Research Project.

Products – any products developed and/or manufactured based upon and/or in connection with the Patent Rights.

Licensee has developed confidential and proprietary technology relating to microRNA sequences including an algorithm for the prediction of microRNAs, techniques for validation of predicted microRNAs on a given material, microRNA expression profiling technology, analysis algorithms for the detection of biomarkers based on microRNA expression profiling and techniques for establishing the relationships between microRNAs and diseases and has identified a large number of microRNA sequences using certain of its proprietary technology and/or proprietary materials.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 362446

License Grant
Licensor possesses proprietary technology and know-how related to the research, discovery, identification, synthesis and development of single-stranded oligonucleotide miRNA Antagonists.

Licensor hereby grants to English Licensee, effective as of the date of such exercise of the relevant Program Option or the date of operation of such provision under this Agreement, a worldwide, exclusive, royalty-bearing, sublicenseable license in the Field, under the Licensor Technology and Licensors’ rights under any Collaboration Technology,
(a) to Develop miRNA Compounds and miRNA Therapeutics,
(b) to Manufacture miRNA Compounds and miRNA Therapeutics, and
(c) to Commercialize miRNA Compounds and miRNA Therapeutics.

License Property
miRNA shall mean a structurally defined functional RNA molecule usually between 21 and 25 nucleotides in length, which is derived from genetically-encoded non-coding RNA which is predicted to be processed into a hairpin RNA structure that is a substrate for the double-stranded RNA-specific ribonuclease Drosha and subsequently is predicted to serve as a substrate for the enzyme Dicer, a member of the RNase III enzyme family; including, without limitation, those miRNAs exemplified in miRBase (http//microrna.sanger.ac.uk/). To the extent that scientific developments after the Effective Date would lead experts in the field of miRNA to expand this definition of miRNA, the Parties agree to discuss redefining miRNA for purposes of this Agreement; provided, however, that nothing contained herein shall require any Party hereto to expand this definition. The miRNAs exemplified in miRBase (http//microrna.sanger.ac.uk/) as of the Effective Date are specified in this Agreement, however, the Parties understand that the content of such database may change after the Effective Date.

miRNA Compound shall mean a compound consisting of a miRNA Antagonist. For purposes of clarity, miRNA Compound excludes (a) miRNA Precursor Antagonists and (b) miRNA Mimics.

miRNA Antagonist shall mean a single-stranded oligonucleotide (or a single stranded analog thereof) that is designed to interfere with or inhibit a particular miRNA. For purposes of clarity, the definition of “miRNA Antagonist” is not intended to include oligonucleotides that function predominantly through the RNAi mechanism of action or the RNase H mechanism of action.

miRNA Mimic shall mean a double-stranded or single-stranded oligonucleotide or analog thereof with a substantially similar base composition as a particular miRNA and which is designed to mimic the activity of such miRNA.

miRNA Pool shall mean a prioritized list of ten (10) miRNAs to be identified in accordance with the procedures set forth in the Initial Research Plan and from which list Licensee shall select up to four (4) Collaboration Targets in accordance with the terms hereof, which list shall exclude (a) any Collaboration Target once selected by Licensee, including any Former Targets,

miRNA Precursor shall mean a transcript that originates from a genomic DNA and that contains, but not necessarily exclusively, a non-coding, structured RNA comprising one or more mature miRNA sequences, including, without limitation, (a) polycistronic transcripts comprising more than one miRNA sequence, (b) miRNA clusters comprising more than one miRNA sequence, (c) pri-miRNAs, and/or (d) pre-miRNAs.

miRNA Precursor Antagonist shall mean a single-stranded oligonucleotide (or a single stranded analog thereof) that is designed to bind to a miRNA Precursor to prevent the production of one or more miRNAs. For purposes of clarity, the definition of “miRNA Precursor Antagonist” is not intended to include oligonucleotides that function predominantly through the RNAi mechanism of action or the RNase H mechanism of action.

miRNA Therapeutic shall mean a therapeutic product having one or more miRNA Compounds as an active ingredient(s).

Field of Use
The programs of interest to Licensee are in the areas of inflammation and immunology.

Field shall mean (a) the treatment and/or prophylaxis of any or all Indications and (b) also, to the extent that Licensor or Licensee, whichever is the licensing Party hereunder, Controls diagnostic rights, the diagnosis of any or all Indications, to the extent such diagnostic rights are necessary or important to Commercialize a Licensed Product or where the absence of Control by the Commercializing Party, of diagnostic rights could reasonably be considered to materially adversely affect the sales of the Licensed Product.

IPSCIO Record ID: 280643

License Grant
The Parties have an agreement to develop technology useful for in vitro and/or in vivo target identification and/or target validation using RNAi and to develop RNAi therapeutic products.

For the RHOA Target, pursuant to the terms of the Original Agreement, Licensor selected the RHOA Target for the development of RNAi Products directed toward such Target (RHOA Products) and Licensee has an opt-in right for further development and commercialization of RHOA Products.

For the royalty bearing products, the Opt-Out Party/Licensor grants the Continuing Party a license under and to Licensor Technology, that is applicable to such Royalty-Bearing Product, to Develop, Manufacture and Commercialize such Royalty-Bearing Product in the Field in the Territory.

For the Profit-Sharing Products
For Development Licenses, Licensor grants a worldwide license in the Territory, with a right to sublicense to its Affiliates, under Licensor Target Identification and Target Validation RNAi Patent Rights, under Licensors interest in Joint Collaboration Patent Rights and Joint Collaboration Inventions, under Licensor Technology Collaboration Inventions, to Licensor RNAi Technology and under Licensor-Assigned Therapeutic Collaboration Inventions, for the sole purpose of in vitro and/or in vivo target identification and/or target validation research relating to drug discovery and/or development activities of Licensee and/or its Affiliates, including in collaborations with Third Parties in which Licensee and/or its Affiliates has any rights to discoveries made.

For Commercialization Licenses,  Licensor grants a license under and to any and all Licensor Technology to Commercialize Profit-Sharing Products in the Field in the Territory.

The foregoing license shall be Exclusive, Co-exclusive or Non-exclusive, depending upon the time period.

License Property
The developed technology will relate to in vitro and/or in vivo target identification and/or target validation using RNAi and to develop RNAi therapeutic products.

Combination Product means a RHOA Product or an RNAi Therapeutic Product combined with any other clinically active ingredient.

Field of Use
The Field shall mean the treatment and/or prophylaxis of diseases in humans with RNAi Therapeutic Products.

RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause highly targeted gene silencing.

Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF),[1] is a signal protein produced by cells that stimulates the formation of blood vessels.  To be specific, VEGF is a sub-family of growth factors, the platelet-derived growth factor family of cystine-knot growth factors.

IPSCIO Record ID: 263518

License Grant
Licensee receives from the Israeli Licensor a co-exclusive, sublicenseable license under the technology and collaboration technology to conduct collaborative development of development targets, compounds and products.

If Licensee exercises its option with respect to a development target and the parties enter into a license agreement, Licensee receives an exclusive, sublicenseable, license under our technology and collaboration technology to exploit compound and products with respect to such development target.

Licensee initially selected two development targets, including Glycogen Storage Disease III, and the parties agreed to a list of eight additional reserved targets related to rare diseases for which Licensee has the exclusive right to evaluate for collaborative development. During the reserved target exclusivity period Licensee may substitute a reserved target for a selected target, and/or exercise an expansion option by payment to us, whereby a reserved target will be deemed an additional target (and will preclude an additional reserved target in place of the converted reserved target). Further, during the reserved target exclusivity period, Licensee may replace a reserved target with a proposed new target, subject to certain conditions including whether we have the ability to partner such new target.

The Agreement additionally provides for limitations on our activities with third parties utilizing LUNAR lipid-mediated delivery technology with respect to a development target for a specified period of time. During the reserved target exclusivity period, we have agreed to exclusivity with respect to any product containing mRNA, including modified mRNA, or UNA oligomer with respect to such reserved target, and will first offer Licensee a right of first negotiation for any other RNA product or a product utilizing the LUNAR delivery technology with respect to such reserved target. The reserved target restrictions terminate upon expiration of the reserved target exclusivity period for each target, which may be extended on a reserved target-by-reserved target basis upon payment of an exclusivity extension fee.

On a reserved target-by-reserved target basis, following the target exclusivity period, Licensee receives an exclusive right of first negotiation to obtain an exclusive license to exploit RNA products with respect to such reserved target. Following the reserved target right of first negotiation period, if the parties have not entered into an agreement during a specified time period, the rights of Licensee terminate and we may grant a license or enter into a third-party arrangement with respect to such reserved target.

License Property
The collaboration technology specifically relates to the composition or formulation of a particular compound or product, or any method of using, making or administering a particular compound or product, and, all improvements to LUNAR lipid-mediated delivery technology and/or UNA oligomer chemistry.

The proprietary lipid nanopartical deliver system, LUNAR®, enables multiple nucleic acid medicines.  LUNAR® lipid-mediated delivery technology includes a diverse, growing library of over 150 proprietary lipids that Licensor rationally designed to be versatile, maximizing efficacy and increasing tolerability of a diverse selection of nucleic acids, target cell types and routes of administration. A key feature of our LUNAR lipids is their biodegradability, decreasing the undesired effects caused by lipid accumulation that are associated with tolerability issues present in other lipid-mediated RNA medicine delivery platforms.  LUNAR® and nucleic acid technologies are covered by a patent portfolio of 152 patents and patent applications, issued in the United States, China, Europe, Japan and other countries.

Unlocked Nucleic Acid (UNA) – are RNA analogues in which the C2’-C3’ bond of the ribose ring is absent. UNA chemistry technology can potentially be applied to multiple types of RNA medicines including mRNA, siRNA, microRNA and guide RNAs for gene editing. One or more UNAs can be positioned strategically along a nucleic acid strand to manipulate the chemical properties of the molecule.  UNAs can potentially improve the efficiency and specificity of siRNA-mediated protein suppression. siRNAs are short double-stranded RNA molecules. Once inside the cell, they become part of the RNA-induced silencing complex (RISC) and are split into two single siRNA strands. One of these strands stays with RISC and binds to any mRNA with a complementary sequence. If the wrong siRNA strand stays with RISC, it can bind to different mRNAs than the target mRNA and therefore inhibit translation of other proteins. This is an undesired off-target effect and is one of the major barriers to developing effective siRNA medicines. Incorporating a single UNA into siRNA molecules can make one of the strands preferentially bind to RISC improving specificity. Additionally, incorporation of UNA modifications can reduce susceptibility of the siRNA to nuclease degradation, improving the efficiency of siRNA-mediated protein suppression.  The comprehensive suite of UNA technology patents for therapeutic and reagent use, enabling Licensor to operate freely and to independently pursue nucleic acid therapeutic candidates incorporating this technology.

The Agreement provides that each party owns their respective collaboration know-how and collaboration patents and jointly own all joint collaboration know-how and joint collaboration patents.

Field of Use
This partnering is to develop up to ten mRNA therapeutic candidates for certain rare disease targets.  Target means any single protein (i.e., a protein designated by a unique NCBI reference sequence but including all of its naturally-occurring mutations and variants) that could be used as a potential treatment for a rare or ultra rare disease and that is expressed in the liver, including  Glycogen Storage Disease Type 3 (GSD), caused by genetic mutations in the glycogen debranching enzyme, known as  AGL, which leads to glycogen accumulation in liver and muscle.  There are approximately 10,000 patients worldwide with this type of GSD, who experience enlarged liver, increased fats in the blood, low blood sugar, decreased stature and late-onset muscle weakness.

The Licensed Field is for the diagnosis, prevention or treatment of human diseases.

IPSCIO Record ID: 352695

License Grant
University grants an exclusive, worldwide license in the Patent Rights to make, have made, use, offer for sale, sell, have sold and import Licensed Products in the Field.
License Property
The patents include
–  Allele-specific RNA Interference;
–  In Vivo Production of Small Interfering RN As that Mediate Gene Silencing;
–  RNA Interference for the Treatment of Gain-of-Function Disorders;
–  Novel AAVs and Uses Thereof;
–  CNS Targeting AAV Vectors and Methods of Use Thereof;
–  Methods and Compositions for Controlling Efficacy of RNA Silencing;
–  Methods and Compositions for Enhancing the Efficacy and Specificity of Single and Double Blunt-Ended siRNA; and,
–  Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi.
Field of Use
The Field of use is the treatment of human diseases using gene therapy applications.  Any commercial sale of research reagents covered by the Patent Rights is specifically excluded
from the Field.

The gene therapy approach uses AAV (adeno-associated virus) vectors, which are modified, non-replicating versions of AAV, and which we believe are ideal vectors for CNS gene therapy.

The Licensee expects to utilize established and novel techniques for dosing and delivery of our AAV gene therapies to the CNS.

IPSCIO Record ID: 289212

License Grant
Licensor grants a perpetual, non-exclusive, worldwide license, with the right to sub- license, under the `277 patent, the `582 patent, and any patents issuing from International Application No. PCT/US96/19698, any and all continuing applications, divisional applications, continuation-in-part applications, reissues, extensions, renewals and reexaminations thereof, and any U.S. and foreign counterparts thereof. In addition, Licensor agrees not to file any future patent infringement actions against Licensee for Licensees use of ThermoFluor Screening Technology that is consistent with the terms of this Agreement.
License Property
Licensor is a biopharmaceutical company dedicated to the development of a novel class of small molecule drugs that regulate gene expression. The Licensors lead therapeutic candidate is a novel anti-HIV compound that acts by inhibiting a viral protein/RNA interaction that is critical for the expression of viral structural proteins and essential for virus production.

Licensor is the owner of U.S. Patent 5,585,277, and U.S. Patent No. 5,679,582.

Atlas Technology shall mean the methods and processes generally disclosed in the specifications and claims of the `277 patent, the `582 patent and/or International Application No. PCT/US96/19698.

ThermoFluor Screening Technology shall mean the methods, processes and apparatus generally disclosed in the specifications and claims of U.S. Patent No. 6,020,141 and/or allowed U.S. Patent Application Serial no. 08/853,459.

Licensor was granted a limited, nonexclusive license to the method claims of ThermoFluor screening technology. As part of this settlement agreement, until March 7, 2003, Licensee is precluded from using ThermoFluor screening technology in the Hepatitis C Virus infection area as part of collaborative agreements or as part of our internal drug programs. In addition, Licensee is precluded from using ThermoFluor screening technology as part of more than one collaboration agreement in the area of infection.

Field of Use
Licensee Internal Program(s) shall mean drug discovery and/or development program(s) in any therapeutic field conducted for and by Licensee on-site at a Licensee facility.

During the Restriction Period, Licensor may refer to Licensee any third parties that have requested that Licensor screen multiple targets to identify leads or drugs that are effective in any field other than Infection.

Licensee shall be free to use ThermoFluor Screening Technology without restriction in any Licensee Internal Program, except in the Hepatitis C Virus Field during the Restriction Period, and to license or transfer, in any manner, any compounds discovered or optimized through such use of ThermoFluor Screening Technology. Licensee shall not use ThermoFluor Screening Technology in the Hepatitis C Virus Field during the Restriction Period.

ThermoFluor screening process and our ability to rapidly select and synthesize compounds from our libraries compress an important segment of the R&D process, from assay set-up to the generation of a series of lead compounds with potential in vivo efficacy, from fourteen to thirty months at many pharmaceutical companies to as little as seven to ten months. This is expected to reduce resources required and development costs per target, allow more targets to be discovered with a given set of resources and accelerate time to market of successful drugs

Licensee is a post-genomics drug discovery company that has developed a unique integration of proprietary technologies to provide an accelerated and improved methodology for gene-to-clinic small molecule drug discovery.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.